Merck & Co., Inc.
http://www.merck.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Merck & Co., Inc.
AAOS 2021: A Closer Look At Think Surgical’s Active, Open-Implant Orthopedic Robot And What’s Ahead
Medtech Insight sat down with Think Surgical’s CFO Paul Weiner at the recent AAOS conference to discuss the roll-out of the next-generation TSolution One TKA robot and company plans.
Stock Watch: Summit’s Stock Plummets
What on earth would make a biotech company change the primary endpoint half way through a Phase III program and not discuss it with the FDA? There are at least two scenarios, neither of them good.
Data PROpel Lynparza To Potential Prostate Cancer Megablockbuster
The Phase III PROpel study has shown that a combination of AstraZeneca's Lynparza and Johnson & Johnson's Zytiga significantly delayed disease progression as a first-line treatment for men with metastatic castration-resistant prostate cancer.
First Pre-Revenue Biotech IPO Rejection By 'China’s Nasdaq'
The STAR Market of the Shanghai Stock Exchange has called a halt to the potentially third-largest biotech IPO this year in an apparent deterrent to the in-licensing model.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Abmaxis
- Acacia Biosciences
- Afferent Pharmaceuticals
- ArQule, Inc.
- Avecia Biologics Limited
- Banyu Pharmaceutical Co., Ltd.
- Calporta Therapeutics
- cCAM Biotherapeutics Ltd.
- Cubist Pharmaceuticals, Inc. (Adolor Corporation (ADLR)
- Calixa Therapeutics, Inc.
- Optimer Pharmaceuticals, Inc.
- Trius Therapeutics, Inc.)
- Idenix Pharmaceuticals, Inc.
- Immune Design Corporation
- Inspire Pharmaceuticals, Inc.
- IOmet Pharma
- iOnctura SA
- Integrated Therapeutics Group
- Merck Sharp & Dohme (MSD) Pharmaceuticals Pvt. Ltd.
- MSD K.K. (Japan)
- Nobilon International BV
- Novacardia
- OncoEthix SA
- Organon BioSciences
- Peloton Therapeutics, Inc.
- Pandion Therapeutics, Inc.
- Rigontec GmbH
- Schering-Plough Corporation
- SmartCells, Inc.
- Tilos Therapeutics, Inc.
- Vallee S.A.
- Viralytics Limited (ASX:VLA)
- Themis Biosciences GmbH